{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:58:03Z","timestamp":1778857083271,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beha.2020.101152","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T21:53:21Z","timestamp":1579902801000},"page":"101152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications"],"prefix":"10.1016","volume":"33","author":[{"given":"Chutima","family":"Kunacheewa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet E.","family":"Manasanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.beha.2020.101152_bib1","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2020.101152_bib2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2020.101152_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/asheducation-2017.1.194","article-title":"Shall we treat smoldering multiple myeloma in the near future?","volume":"2017","author":"Landgren","year":"2017","journal-title":"Hematol Am Soc Hematology Educ Progr"},{"issue":"5","key":"10.1016\/j.beha.2020.101152_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.beha.2020.101152_bib5","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2020.101152_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group","volume":"121","author":"International Myeloma Working","year":"2003","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2020.101152_bib7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2020.101152_bib8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2020.101152_bib9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2020.101152_bib10","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2020.101152_bib11","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.beha.2020.101152_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2020.101152_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ejh.12728","article-title":"Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study","volume":"97","author":"S\u00f8rrig","year":"2016","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2020.101152_bib14","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.beha.2020.101152_bib15","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101152_bib16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101152_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Canc J"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101152_bib18","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2019.37.15_suppl.8000","article-title":"Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria","volume":"37","author":"San Miguel","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2020.101152_bib19","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2020.101152_bib20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2020.101152_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosinol","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2020.101152_bib22","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fernandez de Larrea","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2020.101152_bib23","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41375-018-0155-4","article-title":"Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2020.101152_bib24","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Canc J"},{"issue":"5","key":"10.1016\/j.beha.2020.101152_bib25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2141.2005.05673.x","article-title":"Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma","volume":"130","author":"Rosinol","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2020.101152_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2013-11-535575","article-title":"S0120 G.E.M.S.: genomics encounters MGUS and SMM","volume":"123","author":"Dispenzieri","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2020.101152_bib27","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"34","key":"10.1016\/j.beha.2020.101152_bib28","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2020.101152_bib29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2020.101152_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2016.205","article-title":"Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression","volume":"31","author":"Gonsalves","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2020.101152_bib31","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2014.75","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","author":"Merz","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2020.101152_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2020.101152_bib33","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative group of study and treatment of multiple myeloma","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Canc"},{"issue":"1","key":"10.1016\/j.beha.2020.101152_bib34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.beha.2020.101152_bib35","first-page":"1764","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","author":"Mahesh","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2020.101152_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.beha.2020.101152_bib37","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.beha.2020.101152_bib38","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.beha.2020.101152_bib39","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/bloodadvances.2017005934","article-title":"Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma","volume":"1","author":"Mailankody","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2020.101152_bib40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/01.HS9.0000561764.53887.c0","article-title":"Curative strategy (Gem-Cesar) for high-risk smoldering myeloma: carfilzomib, lenalidomide and dexamethasone (Krd) as induction followed by hdt-Asct, consolidation with Krd and maintenance with Rd: S871","volume":"3","author":"Mateos","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.beha.2020.101152_bib41","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood-2018-99-112656","article-title":"Curativestategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd","volume":"132","author":"Mateos","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101152_bib42","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-99-117871","article-title":"Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"132","author":"Bustoros","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101152_bib43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/blood-2018-154","article-title":"Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2020.101152_bib44","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1200\/JCO.2019.37.15_suppl.8051","article-title":"Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study","volume":"37","author":"Mailankody","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2020.101152_bib45","first-page":"JCO1901740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","author":"Lonial","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2020.101152_bib46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101152_bib47","first-page":"510","article-title":"Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): centaurus, a randomized, open-label, multicenter phase 2 study","volume":"130","author":"Hofmeister","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101152_bib48","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood-2018-99-113467","article-title":"Updated results from the phase 2 centaurus study of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM)","volume":"132","author":"Landgren","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2020.101152_bib49","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood-2019-123205","article-title":"A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)","volume":"134","author":"Manasanch","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2020.101152_bib50","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2020.101152_bib51","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/bloodadvances.2019000300","article-title":"A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis","volume":"3","author":"Manasanch","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.beha.2020.101152_bib52","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.beha.2020.101152_bib53","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMp1803602","article-title":"Immunotherapy combinations in multiple myeloma - known unknowns","volume":"379","author":"Gormley","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.beha.2020.101152_bib54","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin Canc Res"},{"issue":"5","key":"10.1016\/j.beha.2020.101152_bib56","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2020.101152_bib57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-018-0144-x","article-title":"Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma","volume":"8","author":"Atrash","year":"2018","journal-title":"Blood Canc J"},{"issue":"9","key":"10.1016\/j.beha.2020.101152_bib58","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3324\/haematol.2015.124651","article-title":"Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)","volume":"100","author":"Khan","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2020.101152_bib59","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Canc J"},{"issue":"6","key":"10.1016\/j.beha.2020.101152_bib60","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2020.101152_bib61","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262030013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262030013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:56Z","timestamp":1761498356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169262030013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S152169262030013X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101152","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101152"}}